Asia Pacific Hemoglobinopathies Market Size & Outlook
Asia Pacific hemoglobinopathies market, 2018-2030 (US$M)
Related Markets
Asia Pacific hemoglobinopathies market highlights
- The Asia Pacific hemoglobinopathies market generated a revenue of USD 3,125.1 million in 2022.
- The market is expected to grow at a CAGR of 11.6% from 2023 to 2030.
- In terms of segment, sickle cell disease was the largest revenue generating disease type in 2022.
- Sickle cell disease is the most lucrative disease type segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 3,125.1 million |
| Market revenue in 2030 | USD 7,529.7 million |
| Growth rate | 11.6% (CAGR from 2022 to 2030) |
| Largest segment | Sickle cell disease |
| Fastest growing segment | Sickle cell disease |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Thalassemia, Sickle cell disease, Other Hb Variants |
| Key market players worldwide | Sangamo Therapeutics Inc, Global Blood Therapeutics, Bluebird bio Inc, Emmaus Life Sciences Inc, Pfizer Inc, Novartis AG ADR, Prolong Pharmaceuticals, Bioverativ, Gamida Cell, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 20.0% of the global hemoglobinopathies market in 2022.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 7,529.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemoglobinopathies Market Scope
Hemoglobinopathies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific hemoglobinopathies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemoglobinopathies market will help companies and investors design strategic landscapes.
Sickle cell disease was the largest segment with a revenue share of 59.29% in 2022. Horizon Databook has segmented the Asia Pacific hemoglobinopathies market based on thalassemia, sickle cell disease, other hb variants covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific hemoglobinopathies market is estimated to exhibit lucrative growth rate over the forecast period. Presence of a large number of patients suffering from SCD and thalassemia, is expected to propel the market growth in the coming years.
Favorable government initiatives being undertaken, which are aimed at improving the standard of care provided to patients affected with hemoglobinopathies, are contributing to the market growth in the region.
Due to improved healthcare facilities, the burden of SCD and thalassemia is growing in the region. Moreover, various initiatives being undertaken, which aim at promoting awareness about the disorders, and ongoing research to develop new treatment options for treating these conditions are likely to propel the growth of the market.
Reasons to subscribe to Asia Pacific hemoglobinopathies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific hemoglobinopathies market databook
-
Our clientele includes a mix of hemoglobinopathies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific hemoglobinopathies market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific hemoglobinopathies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific hemoglobinopathies market size, by country, 2018-2030 (US$M)
Asia Pacific Hemoglobinopathies Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
